|
Originally published In Press as doi:10.1074/jbc.M105455200 on August 30, 2001
J. Biol. Chem., Vol. 276, Issue 46, 43087-43094, November 16, 2001
Identification of a Site on Mannan-binding Lectin Critical for
Enhancement of Phagocytosis*
Meenakshi
Arora,
Esther
Munoz, and
Andrea J.
Tenner
From the Department of Molecular Biology and Biochemistry,
University of California, Irvine, California 92697
Received for publication, June 13, 2001, and in revised form, August 27, 2001
 |
ABSTRACT |
Mannan-binding lectin (MBL) constitutes an
important part of the human innate immune defense system. It has been
shown to mediate the activation of complement upon binding to specific microbial carbohydrate motifs, to directly opsonize organisms, and to
enhance the phagocytosis of targets suboptimally opsonized with IgG or
complement components C3b or C4b. This enhancement of phagocytic
activity induced by MBL and other molecules that contain a
collagen-like region contiguous with a pattern recognition domain is
mediated by a 126,000 Mr surface glycoprotein, designated C1qRP. Although it has been known that the
collagen-like domain of these "defense collagens" contains the
interaction site(s) that triggers this enhancement of uptake, the
specific interaction site has not been identified. To address this
issue, wild type and mutant MBL constructs were generated, inserted
into baculovirus, expressed in Sf9 cells, and the recombinant
MBL (rMBL) proteins purified by mannan affinity chromatography. The
effect of wild type and mutant rMBL on the phagocytosis of targets
suboptimally opsonized with IgG or with IgM and C4b by human peripheral
blood monocytes was then assessed. Two mutants, one of which has five GXY triplets deleted below the kink region of MBL and the
other one having only two of the GXY triplets deleted below
the kink, failed to enhance phagocytosis, suggesting the importance of
the specific sequence GEKGEP in stimulating phagocytic activity.
Similar sequences were detected in other defense collagens, implicating the consensus motif GE(K/Q/R)GEP as critical in mediating the enhancement of phagocytosis through C1qRP. Clarification of
specific ligand-C1qRP interactions should facilitate the
investigation of the signal transduction processes involved in the cell
activation, as well as provide the basis for the design of specific
modulators of the functions mediated by this receptor.
 |
INTRODUCTION |
Vertebrates have developed very complicated defense mechanisms,
including innate and adaptive immune systems to prevent infection by
pathogenic microorganisms. Although effective individually, the
complement system and phagocytic cells also interact with each other
synergistically to facilitate the innate (first-line) immune defense
system. Mannan-binding lectin
(MBL),1 a serum protein of
hepatic origin belonging to a family of
Ca2+-dependent collagenous lectins, is an
important component of the innate immune system (1, 2). MBL is a
multichain molecule of up to six subunits; each subunit consists of
three identical 32-kDa polypeptide chains that contain a cysteine rich
NH2-terminal domain, which stabilizes the collagen
-helix of the second domain and a third COOH-terminal
carbohydrate-binding domain (3). The collagen-like domain consists of
18-20 repeats of the triplet sequence GXY (where
Y is often Pro or Hyp) (3). Human MBL is present in blood as
a mixture of oligomers of its subunit with trimers/tetramers and
pentamers/hexamers, constituting ~80 and 15% of the pool,
respectively. MBL activates the complement system via two serum
proteases, MASP-1 and MASP-2 (4-6). This lectin pathway of complement
activation leads to complement-dependent lysis by a process
that requires C4, C2, C3, and the macromolecular attack complex
(7, 8).
In addition to providing protection to the host through triggering
complement activation, MBL is a member of a family of proteins called
the defense collagens (9). This group of proteins contains a
characteristic NH2-terminal collagen-like domain as well as a globular carboxyl-terminal domain that includes recognition sites for
what Medzhitov and Janeway (10) designated as
pathogen-associated molecular patterns. All members of this family,
which includes C1q, pulmonary surfactant proteins A and D (SP-A and
SP-D), conglutinin, and ficolin (11), have been shown to play a
role in defense against potential pathogens (1, 12-14). Previous work
has shown that MBL, C1q, and SP-A enhance FcR-mediated phagocytosis by
both monocytes and macrophages in vitro and stimulate
CR1-mediated phagocytosis in human culture-derived macrophages and in
phorbol ester-activated monocytes (15, 16); this enhancement is
mediated via a 126,000 Mr surface glycoprotein
designated C1qRP (16, 17).
It has been shown earlier that the enhancement of phagocytic activity
is mediated via the collagen-like fragment of C1q, as the isolated
pepsin-resistant fragments, but not the pepsin-sensitive collagenase-resistant fragments, retain full activity (18). Thus, it
has been hypothesized that common structural features of the
collagen-like domains may provide a basis for this biological function
of MBL, C1q, and SP-A. In addition, it was known that C1q in complex
with C1r and C1s had no ability to enhance phagocytosis, suggesting
that the regions above or below the kink region (where C1r and C1s
associate with C1q) would be likely candidates for the receptor
interaction domain.
This study was undertaken to determine the exact interaction site in
the collagen-like domain of these defense collagens that mediates the
enhancement of phagocytosis. A region containing a common amino acid
sequence was noted when sequences of MBL and C1q near the kink region
were examined. We used the baculovirus expression system for generating
recombinant MBL and various mutants of MBL. The effect of the purified
rMBL and mutant MBL on the FcR and CR1-mediated phagocytosis by
monocytes was then assessed. Two of the mutants constructed with a
common deletion of two GXY triplets below the kink did not
enhance phagocytosis, whereas wild type rMBL and other mutants retained
activity. These data provide evidence that this sequence is necessary
for the C1qRp-mediated enhancement of phagocytosis.
 |
EXPERIMENTAL PROCEDURES |
Media, Reagents, and Antibodies--
Pfu polymerase
was purchased from Stratagene (La Jolla, CA). Restriction enzymes and
RPMI were purchased from Life Technologies, Inc.
Ex-CellTM X401 was purchased from JRH Biosciences (Lenexa,
KS). Sheep erythrocytes were purchased from Colorado Serum (Denver,
CO). The human serum albumin (HSA), obtained from the American Red
Cross, was prepared by Baxter HealthCare Corp. (Glendale, CA). C1q was
obtained from plasma-derived human serum by the method of Tenner
et al. (19) and modified by Young et al. (20).
All other reagents used, except where noted otherwise, were obtained at
the highest quality available from Sigma.
Monoclonal anti-MBL antibodies 2A9, h1.2, and 3F8 were a generous gift
from Dr. Gregory Stahl, Harvard Medical School, Boston (21). Polyclonal
anti-MBL, anti-serum 1173, was derived after immunization with MBL,
which was purified from normal human serum. The IgG fraction was
purified using octanoic acid and ammonium sulfate. Anti-C1qRp
monoclonal antibody R3 (IgM), generated by immunization with cell
membrane C1q-binding proteins as previously reported (22), was purified
from ascites fluid using the ImmunoPure IgM purification kit according
to the instructions of the manufacturer (Pierce). IgM antibodies
against sheep red blood cells were purchased from Diamedix (Miami).
Antibodies against sheep red cells (hemolysin) were purchased from
Cordis Laboratories (Miami), and IgG was purified from hemolysin using
a protein G column.
Cells--
Human peripheral blood monocytes were isolated by
counter-flow elutriation using a modification of the technique of
Lionetti et al. (23) as described (24). Blood units were
collected into CPDA1 by the University of California, Irvine, Medical
Center Blood Bank (Orange, CA). More than 92% of the cells in each
preparation were monocytes according to size analysis on a Coulter Channelyzer.
Construction of Recombinant MBL Molecules--
Clones containing
the cDNA of the wild type human MBL (hMBL) and hMBL with amino
acids 69-74 deleted (Del) were kindly donated by Dr. Keith A. Joiner
(Yale University, New Haven, CT). These cDNAs were 1324 and 1306 base pairs, respectively, as a result of HpaI digestion of
MBL cDNA. Using wild type hMBL cDNA, the different recombinant
molecules of MBL were generated by joining two PCR products, A and B,
as shown in Fig. 1. The primers were designed to keep the correct reading frame and the appropriate restriction sites (SmaI and XhoI) for cloning.
The primers used in PCR A and B of mutants A (kink removed), 2, 3,
and 5 were the following: mutant A, PCR A, 5' = SacI
(GGGGAGCTCCACCGCGGTGGCGGC) and AB
(TCCCCCGGGTTCCCCCTTTTCTCCCTTGG); PCR B, 3' = XhoI (CCCCTCGAGGTCGACGGTATCGATAAG) and
AF (TCCCCCGGGCTCAGAGGCTTACAGGGC); mutant 2, PCR
A, 5' = SacI (as above for mutant A) and 2B (CTTGGTGCCATCACGCCCATC); PCR B, 3' = XhoI (as above for
mutant A) and 2F (TCCCCCGGGCAAGGGCTCAGAGGCTTAC);
mutant 3, PCR A, 5' = SacI and 3B
(TCCCCCGGGGAAGCCGTTGATGCCTGG); PCR B, 3' = XhoI and 3F
(TCCCCCGGGGAAAAGGGGGAACCAGGC).=; mutant 5, PCR A, 5' = SacI and 5B
(TCCCCCGGGGAAGCCGTTGATGCCTGG); PCR B, 3' = XhoI and 5F
(TCCCCCGGGCAAGGGCTCAGAGGCTTAC). The sense (F) and antisense
(B) primers of the mutants A, 3 and 5 have recognition sites for
SmaI in the 5' flanking region, marked by bold letters. The
2B primer for mutant 2 does not contain a recognition site, and the
cloning was done as a blunt-ended insert.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 1.
Schematic flow sheet for generation of mutant
human recombinant MBL plasmids. PCR products were engineered such
that the desired mutant MBL would be created upon incorporation of the
sequences into Bluescript KS+. pBS was used to construct the mutant
sequences, which were then cloned into the baculovirus vector pVL1393
for subsequent expression in Sf9 cells (see "Experimental
Procedures").
|
|
The PCR B product for each mutant was first cloned into Bluescript KS+.
The PCR A fragment and the pBS-PCRB clones were then digested by
SmaI and ligated to form each mutant construct. For all
mutant constructs the orientation of the PCR A insert was determined by
restriction mapping and the full-length recombinant human MBL (rhMBL)
cDNA was sequenced and then introduced into the baculovirus
transfer vector, pVL1393 (PharMingen, San Diego, CA) according to the
manufacturer's instructions.
Expression and Purification of the Recombinants MBL
Proteins--
The recombinant vectors were purified and then
co-transfected with linear AcNPV DNA into Sf-9 cells. Transfection was
performed as described in the Baculovirus Expression System Manual from PharMingen. Recombinant baculovirus were amplified into high titer stocks. For protein expression, the recombinant virus stock was used to
infect Sf-9 cells, and the cells were cultured at 27 °C for 5 days.
Recombinant proteins were secreted from infected Sf-9 cells in
serum-free Ex-CellTM 401 medium in the presence of 0.3 mM L-ascorbic acid to enhance the hydroxylation
of lysine and proline residues (25). The supernatants were extensively
dialyzed against TBS-T Ca2+ (50 mM Tris, 1 M NaCl, 0.05% Tween 20, 20 mM
CaCl2, pH 7.8) and then incubated with agarose-mannan beads
(Sigma) for 2 h at 4 °C. After washing, proteins were eluted
with TBS-T EDTA (50 mM Tris, 1 M NaCl, 0.05%
Tween 20, 10 mM EDTA, pH 7.8). The eluted fractions were
recalcified to 40 mM CaCl2 and assayed by ELISA (see below) for MBL, and the positive fractions were pooled. The procedure was repeated on a second mannan affinity column to enhance purity (26). The eluted recombinant proteins were concentrated using
Centricon 30 (Millipore, Bedford, MA). Proteins were then subjected to
SDS-polyacrylamide gel electrophoresis (PAGE) under reducing (50 mM dithiothreitol) and nonreducing conditions and the
silver-stained gel compared with Western blot patterns to determine purity.
ELISA for MBL--
MBL concentrations were assessed using a
sandwich ELISA. Briefly, microtiter plates were coated with polyclonal
anti-MBL antibody at a concentration of 10 µg/ml (100 µl/well) in
coating buffer (0.1 M carbonate buffer, pH 9.6) and
incubated overnight at 4 °C. The microtiter plates were washed three
times with phosphate-buffered saline containing 0.05% Tween 20 (PBS-T)
and blocked for 1 h at 37 °C by adding 200 µl of PBS
containing 3% milk to each well. Samples and MBL standards were loaded
into wells in duplicate, incubated at room temperature for 2 h,
and washed as described before. Monoclonal anti-MBL (2 µg/ml) diluted
in PBST-1% milk (100 µl/well) was added to each well and incubated
at room temperature for 1 h. After washing, plates were incubated
with peroxidase-conjugated donkey anti-mouse IgG (Jackson
ImmunoResearch Laboratories, West Grove, PA) for 30 min at room
temperature. Color was developed using OPD as the substrate and the
absorbance at 405 nm read on a microplate reader (Molecular Devices,
Menlo Park, CA). Serum MBL standard, kindly provided by Prof. Kawasaki
(Kyoto University, Kyoto, Japan), was used to calibrate our plasma standard.
Circular Dichroism (CD)--
Circular Dichroism was recorded
using a Jasco J720 spectropolarimeter. Data were collected at 0.5-nm
intervals, and four scans were averaged but not smoothed. A cell of
1-mm path length was used. Protein concentration used was 1 mg/ml in
TBS-T Ca2+.
Phagocytosis Assay--
Sheep erythrocytes bearing anti-sheep
red blood cells IgG (EAIgG) or anti-sheep red blood cells
IgM and C4b (EAIgMC4b) were used as targets for the
phagocytic assays and prepared as described previously (27). Briefly,
8-well LabTek chambers (Nalgene, Naperville, IL) were coated with
varying concentrations of C1q, HSA, and the different recombinant MBL
molecules. Monocytes were added to each chamber (6.25 × 104 cells/well) and centrifuged at 50 × g
for 3 min, and the cells were allowed to adhere for 30 min at 37 °C,
5% CO2. Targets were then added (107/100 µl)
and incubated for 30 min at 37 °C, 5% CO2 to allow
phagocytosis to occur. Although monocytes readily bind and ingest
IgG-opsonized particles and avidly bind C4b-coated particles, these
resting phagocytes do not ingest particles bound via CR1 unless
activated with phorbol esters (28). Therefore, in the experiments in
which monocytes were assessed for CR1-mediated phagocytosis, 10 ng/ml of phorbol dibutyrate was added with the opsonized targets. After removing targets that were not cell-associated, noningested
EAIgG were lysed in hypotonic buffer. Cells were then fixed
and stained, and phagocytosis was quantitated using light microscopy.
The number of opsonized targets ingested/100 effector cells is defined
as the phagocytic index (PI), whereas the percentage of effector cells
(monocytes) ingesting at least one E target is defined as the percent
of phagocytosis. In each experiment, duplicate sample wells per
condition were used, and >200 cells were scored per well. All
experiments were reproducible with experiments performed on separate
days with different donors.
In some experiments, monocytes (5 × 105/ml) were
pretreated for 20 min at room temperature with 20 µg/ml R3 or control
mouse monoclonal IgM (Sigma) prior to a 2-fold dilution and the
addition of the cells to chambers as described above. Statistical
analysis was performed using Sigma Stat, version 2.01, software (SPSS, Chicago, IL). The coating efficiency of all the proteins was checked using a BCA protein assay kit (Pierce).
 |
RESULTS |
Biosynthesis and Secretion of Wild Type and Mutant MBLs Expressed
in Sf9 Cells--
The amino acids deleted for each mutant and
their localization within the MBL molecule are presented in Fig.
2. Both wild type and mutant recombinant
hMBL proteins were expressed in Sf9 cells and secreted as documented by
the presence of immunoreactive MBL protein in culture media. The levels
of mutant protein secreted into the cell culture media were similar to
that of wild type MBL (Table I),
suggesting that the mutations introduced into the collagen-like domains
did not seriously affect the biosynthesis and secretion of MBL under
our experimental conditions. ELISA assays demonstrated that the
recovery of these proteins (Wt, Del, 2, 3, 5, and A) after
purification was 37-56% of the starting material (Table I).
Interestingly, mutant A, which does not have the break in the
Gly-X-Y sequence that is proposed to mediate the
bend or kink in the collagen domain of the wild type protein, was also
expressed suggesting that lack of this structural characteristic has no
deleterious effect on expression.

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 2.
Schematic representation of the recombinant
MBL proteins. The hexameric form of hMBL is shown. Each monomer is
a triplet of identical polypeptide chains. As depicted, the MBL
molecule consists of a collagen-like domain consisting of 19 Gly-Xaa-Yaa triplets, a neck region, and finally a globular
COOH-terminal carbohydrate recognition domain. The location of
each mutant deletion is shown in the schematic. The corresponding
sequence deleted in each mutant is as follows. W,
wild type; Del, amino acids 69-74 deleted; A,
amino acids 43 and 44, which introduce a disruption in the
GXY pattern and thus create the kink, deleted;
2, amino acids 37-42 deleted; 3, amino acids
28-36 deleted; and 5, amino acids 28-42 deleted.
|
|
Biochemical Assessment of Purified Recombinant
MBL--
SDS-PAGE of native and recombinant wild type hMBL under
reducing conditions revealed that native hMBL migrates as a single band
with an apparent molecular mass of 29 kDa, whereas rhMBL appears with a
slightly lower apparent molecular mass under the same conditions
(Fig. 3A, left), both of which
were identified as human MBL by immunoblot analysis (data not shown).
This difference in molecular mass between native and recombinant
wild type protein may be attributable to differences in glycosylation
between mammalian cells and insect cells (29) and/or the lack of
hydroxylation of proline residues. (An additional protein band with an
apparent molecular mass of 24 kDa is reactive with anti-MBL in Western blots; this is presumed to be a proteolytic fragment of MBL.) SDS-PAGE
of mutant rMBL under reducing conditions (Fig. 3B, left) reveals that mutants have slightly faster mobility as compared with
wild type MBL, as could be anticipated from the deletion of amino acids
from their sequences.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 3.
Electrophoretic analysis of serum MBL and
recombinant MBL proteins secreted by baculovirus-infected Sf-9
cells. Proteins were subjected to SDS-PAGE under reducing
(left panels) and nonreducing conditions (right
panels) (12.5 and 10% acrylamide, respectively) and detected by
silver staining. A, rhMBL migrates slightly faster than
native MBL purified from serum (serum MBL). B,
wild type (Wt) and mutant MBL proteins purified from 5-day
culture media of baculovirus-infected Sf9. The migration
positions of molecular mass markers are shown to the left of
each gel.
|
|
SDS-PAGE of rMBL and its various mutants under nonreducing conditions
(Fig. 3B, right) shows that the purified proteins migrate as
several bands that correspond to multiple covalently associated (via
disulfide bonds) oligomeric species. rMBL is similarly characterized by
low-order oligomeric structures compared with native MBL (Fig. 3A, right). Because it was possible that deletion of some
GXY triplets could cause a perturbation of the collagen
helix leading to loss of activity, the CD spectra of the wild type was
collected and compared with that of the 2, 5, and Del mutants. No
differences in the CD spectra of any of the variants were observed,
suggesting that the mutants retained their collagen-like helical
secondary structure even after the deletion of specific GXY
triplets (Fig. 4). Sedimentation profiles
of mutant MBL proteins were also compared with wild type recombinant
MBL in sucrose density gradients (10-30%). Fractions were collected
after ultracentrifugation, and the presence of MBL was assayed by
ELISA. The results showed that both 2 and 5 mutants as well as
mutant Del had nearly identical sedimentation profiles as the wild type
MBL (data not shown), indicating similar multimeric structures in 2
and 5 mutants as compared with wild type recombinant MBL. Thus, in
general, all of the mutants of MBL appear to have multimeric structures
similar to wild type rMBL.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 4.
Deletion of specific GXY
triplets does not alter the collagen-like secondary
structure. Circular dichroism spectra of the 2, 5, and Del MBL
were compared with the wild type MBL. Circular dichroism spectra are
presented as millidegrees of ellipticity. Data were collected at 0.5-nm
intervals, and the reported results are the average of 4 scans. The
protein concentration used was 1 mg/ml in TBS-T Ca2+.
|
|
MBL ( 2) and MBL ( 5) Lack Ability to Enhance FcR-mediated
Phagocytosis--
To assess the effect of rMBL and different MBL
mutants on the phagocytosis of sheep erythrocytes suboptimally
opsonized with IgG anti-sheep red blood cells by human peripheral blood
monocytes, purified human monocytes were added to glass slides
previously coated with various concentrations of either HSA, C1q, rMBL,
or different mutants of MBL. After 30 min, IgG-coated targets were added, the mixture was incubated for 30 min at 37 °C, and
phagocytosis was assessed. The data in Fig.
5 demonstrate that wild type rMBL produced in insect cells mimics the enhancing effect of C1q on FcR-mediated phagocytosis of suboptimally opsonized targets. The phagocytic activity was increased in a dose-dependent
manner above that seen with cells adhered to the control protein HSA
when measured both as an increase in the percentage of cells ingesting
the target particles (Percent Phagocytosis, Fig.
5A) and as an increase in the number of targets ingested per
cell (Phagocytic Index, Fig. 5B). Three of the
MBL mutants (A, Del, and 3) were equivalent to wild type MBL in
enhancing FcR-mediated phagocytosis. In contrast, mutants 5 and 2
failed to enhance FcR-mediated phagocytosis (Fig. 5). These findings
were reproducible in that although the absolute amount of phagocytosis
relative to the basal level seen with HSA varied among the experiments,
wild type and mutants A, Del, and 3 MBL consistently augmented
phagocytosis to the same degree as C1q, whereas the mutant MBL proteins
5 and 2 had no such effect. The difference between the ability of
wild type MBL and either the 2 or the 5 mutant to enhance the
phagocytosis was significant (p < 0.001) as analyzed
by Student's t test (n = 4). Table
II presents -fold enhancement of the
percent phagocytosis and phagocytic index mediated by the different
proteins relative to the HSA control (using a coating solution of 8 µg/ml) from four different experiments.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 5.
MBL ( 2) and MBL ( 5) fail to enhance
FcR-mediated phagocytosis. LabTek chambers were precoated with 200 µl of 2, 4, 8, and 16 µg/ml HSA, C1q, or different recombinantly
expressed MBL proteins. Human monocytes were then adhered to the LabTek
chambers. After 30 min of adherence, suboptimally opsonized
EAIgG were added, and phagocytosis was assayed after 30 min. A, the percentage of monocytes ingesting at least one
EAIgG target. B, the number of targets
ingested/100 monocytes (Phagocytic Index). Values presented
are the mean ± S.D. of duplicate samples from one of four similar
experiments.
|
|
Although the failure in mutants 2 and 5 to enhance phagocytosis
could be because of the deletions in these mutants, an alternative possibility is that it was because of a difference in the coating efficiency of mutants 2 and 5 relative to the other active
proteins, resulting in reduced levels of the proteins adhering to the
well. To investigate this possibility, the amount of each MBL protein adhered to the wells was determined. The data in Table
III show that approximately equal amounts
of wild type and mutant proteins were bound per well for all proteins
tested (n = 3). Thus, the common amino acid sequence
deleted in MBL mutants 2 and 5 (GEKGEP) appears to be critical for
enhancing phagocytosis.
MBL ( 2) and MBL ( 5) Lack Ability to Enhance CR1-mediated
Phagocytosis--
In addition to FcR, there are a number of cell
surface molecules present on various phagocytes that bind to and
facilitate ingestion of foreign particles. One such receptor is CR1. To
determine whether the sequence identified by the 2 and 5 mutants
that is important for enhancing FcR-mediated phagocytosis is also
critical for enhancing CR1-mediated phagocytosis, we tested whether
targets opsonized with IgM and C4b (such that they are bound by the
C3b/C4b receptor, CR1) were also ingested to a similar degree upon
interaction of the phagocytes with MBL or various mutants of MBL. Thus,
monocytes were adhered to the wells coated with HSA, C1q, and different mutants of rMBL, EAIgMC4b targets were added to the wells,
and phagocytosis assessed. Similar to FcR-mediated phagocytosis, rMBL and mutants 3, A, and Del augmented CR1-mediated phagocytosis to
roughly the same extent as C1q. In contrast, mutants 5 and 2 failed
to enhance either the percentage of cells ingesting the target
particles or the number of targets ingested per cell (Fig.
6).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 6.
MBL mutants 2 and 5 fail to
enhance CR1-mediated phagocytosis. Human monocytes were added to
LabTek chambers that had been precoated with 8 or 16 µg/ml HSA, C1q,
or various mutants of rMBL. After 30 min of adherence,
EAIgM C4b were added, and phagocytosis was assayed as
described under "Experimental Procedures." A, the
percentage of monocytes ingesting at least one EAIgM C4b
target. B, the number of targets ingested/100 monocytes.
Values presented are the mean ± S.D. of duplicate samples.
|
|
Monoclonal Antibody R3 Inhibits MBL-mediated Enhancement of
Phagocytosis--
Previous experiments from our laboratory had shown
that anti-C1qRP monoclonal antibody was able to inhibit
both C1q- and MBL-mediated enhancement of phagocytosis (16). To
verify the involvement of C1qRP in the enhancement of
phagocytosis by rMBL and its various mutants, monocytes were pretreated
with buffer, R3 (anti-C1qRP), and control IgM antibody for
15 min prior to their addition to wells coated with HSA, C1q, rMBL, or
MBL mutants, and phagocytosis was assessed. R3 antibody inhibited the
number of monocytes engaged in phagocytosis (Fig.
7A) and also the number of
targets ingested by the cells (Fig. 7B). The percent of
monocytes triggered by C1q, wild type rhMBL, and 3 mutant MBL to
phagocytose targets was inhibited by 76.9 ± 2.6, 72.0 ± 3.9, and 73.9 ± 2.7%, respectively, in the presence of anti-C1qRP,
whereas the average inhibition of phagocytic index by R3 was 89.1 ± 14.8% for C1q, 68.7 ± 13.4% for wild MBL, and 60.9 ± 6.9% for
the 3 mutant of MBL. Inhibition of enhancement of phagocytosis was
not observed in parallel samples incubated with control IgM, nor was
there any effect of the R3 antibody on basal phagocytosis seen with
cells adhered to HSA or mutants MBL 2 or 5. These data indicate
that the enhancement of phagocytosis induced by C1q and the active rMBL
proteins requires C1qRP function.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 7.
Monoclonal anti-C1qRP antibody,
R3, inhibits C1q/MBL-mediated enhancement of phagocytosis.
Purified monocytes were preincubated for 15 min at room temperature
with buffer, R3 (anti-C1qRP), or control IgM prior to being
added to chambers precoated with HSA, C1q, or various rMBL (8 µg/ml). After 30 min of adherence, suboptimally opsonized
EAIgG targets were added, and phagocytosis was assayed
after 30 min. A, the percentage of monocytes ingesting at
least one EAIgG target. B, the number of targets
ingested/100 monocytes. Error bars indicate the S.D. of
duplicate wells.
|
|
 |
DISCUSSION |
The generation of rMBL and its mutants provided the reagents for
defining the critical interaction site necessary for
C1qRP-mediated enhancement of phagocytosis. In this study
we have shown that rMBL generated in the baculovirus expression system
is functionally active in enhancing FcR- and CR1-mediated phagocytosis.
Using the recombinant mutant proteins, we have demonstrated that the removal of the sequence GEKGEP (amino acids 37-42) from the
collagen-like domain of MBL abolishes the ability of MBL to enhance
phagocytosis. These data suggest that these two GXY
triplets are critical for the interaction of MBL with cells leading to
the enhancement of phagocytosis.
MBL, SP-A, and C1q, all of which have been shown to increase the
phagocytic activity of cells of myeloid lineage via C1qRP, have similar macromolecular structures with a globular COOH-terminal "recognition" domain that mediates binding to specific sugar or lipid moieties or, in the case of C1q, the Fc domain of specific immunoglobulin molecules and select pathogens (30). The contiguous collagen-like domain has a characteristic interruption in the GXY repeat pattern and hydroxylated amino acids. Previously
reported studies have shown that the C1q cell interaction site that
mediates enhanced phagocytic capacity is located in the collagen-like
portion of the C1q molecule (18, 31). However, because intact C1q has
not been successfully recombinantly expressed in any system, further
localization of the site in the collagen-like domain of defense
collagens that enhances phagocytosis with C1q was not possible. Because
functional MBL has been generated in recombinant expression systems, we
chose to use MBL as the model C1qRP ligand and to construct
various mutants using the baculovirus expression system.
Phagocytosis assays performed using these mutants revealed that wild
type MBL, mutant A, and mutant Del enhanced both FcR- and CR1-mediated
phagocytosis in a manner similar to C1q, whereas the 5 mutant, which
had five GXY triplets deleted below the "kink," did not.
Construction of two mutants, one with a deletion of three of those five
GXY triplets (mutant 3) and the second with the two other
triplets deleted (mutant 2), allowed the localization of the critical
interaction region in that the 3 mutant retained the wild type MBL
ability to enhance phagocytosis, whereas the 2 mutant showed no
ability to enhance phagocytosis. In contrast, a mutant with two
different GXY triplets deleted above the kink (Del) showed
no loss of activity. In addition, deletion of the coding sequence for
the two amino acids responsible for the kink in the collagen-like
structure of MBL adjacent to the implicated sequence (GEKGEP) also
showed no loss of activity. These data together suggest that: 1) the
deletion of any two GXY triplets does not interrupt the
functional activity (mutant Del); 2) deletion of triplets below the
kink does not necessarily nonspecifically destabilize the collagen-like
structure necessary for functional cell interaction (mutant 3); and
3) changes at or near the kink region are not particularly more likely
to induce loss of function (mutant A). Thus, the sequence GEKGEP in the
MBL molecule appears to be critical for the enhancement of phagocytosis.
SDS-PAGE analysis of rMBL and its various mutants showed that all of
the mutants have a similar macromolecular structure, which was
confirmed by similar sucrose density gradient centrifugation profiles.
In addition, CD analysis demonstrated that mutants have similar
secondary structure, and thus loss of phagocytic activity of 2 and
5 mutants is not due to the loss of secondary structure of the
molecule. Furthermore, no statistical difference among the coating
efficiencies of native and mutant MBL proteins was detected, suggesting
that the failure of mutants 2 and 5 to enhance phagocytosis is not
due to a decreased density of protein on the plates.
As reported previously, a monoclonal anti-C1qRP inhibited
the stimulation of phagocytic activity by the active MBL mutants (Fig.
7), indicating that the assessed activity is mediated through C1qRP. The antibody had no effect on the base-line
phagocytosis when cells were assayed in the presence of human albumin
or when mutants 2 and 5 were the proteins coated on the well.
Examination of the amino acid sequence of other defense collagens that
have been shown previously to enhance phagocytosis via
C1qRP revealed that human SP-A and rat and mouse MBL had
the identical sequence, GEKGEP (Fig. 8),
although the sequence in SP-A was found at a considerable distance
above the kink rather than below it. In contrast, the A chain of human
and mouse C1q contains a sequence that is similar but not identical to
the MBL sequence in that the lysine (K) in the GEKGEP is
substituted with a glutamine or an arginine residue, respectively. That
is, the human C1q sequence is GEQGEP, and the mouse C1q A
chain sequence is GERGEP. We postulate that these relatively
conservative amino acid substitutions would have hydrogen-bonding
capabilities similar to the lysine in the MBL and SP-A molecules
and would fulfill a role in the C1qRP-mediated enhancement
of phagocytosis similar to that of the GEKGEP sequence in MBL. In
addition, because C1q is a hexamer of trimers with three distinct
polypeptide chains, A, B, and C, in contrast to the homotrimers of MBL
and SP-A, it appears that only one such motif per trimer is required
for induction of function.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 8.
Comparison of Sequences of MBL, SP-A, and C1q
in different species. The amino acid (AA)
position number is shown as a subscript at the
far left of each sequence.
|
|
Interestingly, five of the six MBL molecules studied, including the
inactive 2 and 5 mutants, have the sequence GQKGDP within their
collagen-like domains. Thus, four of the amino acids
(GXKGXP) in this
motif are not sufficient for activity, suggesting that the two
negatively charged amino acids (GEKGEP) are
critical for the functional interaction. In addition, the presence of
this motif with the conservative substitutions of Gln and Asp
for the glutamic acid residues suggests that the two acidic residues in
the middle of the triplets in this identified active motif are critical
for induction of this function, although location within the protein
structure has not be eliminated as a contributing factor. (It should
also be noted that there is no evidence that this similar 6-amino acid
sequence contributes to activity, because mutant Del lacks the GQK and
yet retains full activity.) As shown in Fig. 8, the murine and human
C1q molecules have the conservative substitutions Gln and Arg for the
Lys in position 3 of the motif, and thus the lysine residue has some flexibility. Taken together, the data implicate the negatively charged
residues (Glu) at positions 2 and 5 of the identified motif as
critical in some way for the functional interaction of MBL with the
cell. Although it is established that these six amino acids are
required for activity, it remains to be established whether only one or
both glutamic acid residues are required, whether the requirement is
only for an acidic amino acid in both positions, and whether any of the
remaining amino acids contribute to the enhancement of phagocytosis. A
model of this region of MBL based on the known crystal structure of a
synthetic collagen peptide (32) presented in Fig.
9 demonstrates a possible orientation of
the residues in this motif.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 9.
Molecular model of residues 37-42 of
MBL. The MBL residues were superimposed on the coordinates of the
three-dimensional structure of a collagen triple helix peptide
consisting of proline-hydroxyproline-glycine repeats (32) using
the Biopolymer module in the Biosym Insight molecular modeling package.
The amino acid side chains were rotated to match the well established
favored rotamers for side chains.
|
|
It should be noted that this sequence and location differ from the
sequence identified as critical for the interaction of C1q with
neutrophils that leads to the induction of superoxide production
in vitro (33, 34). This is consistent with other observations supporting the hypothesis that the cell surface structures involved in the interaction of C1q that leads to enhancement of phagocytic activity is somehow critically different from that which
leads to the induction of neutrophil NADPH oxidase activity and thus
superoxide generation (35, 36).
C1qRP was first detected on professional phagocytic cells
such as peripheral blood monocytes, neutrophils, umbilical cord endothelial cells, microglia, and myeloid cell lines (35, 37, 38).
However, recent reports investigating the tissue expression of this
receptor suggest that other cell types such as endothelial cells (39,
40), early hematopoietic cells in the fetal mouse (41), and NK cells in
rat (42) also express C1qRP, indicating that
C1qRP may be important in hemopoietic and vascular
development and other cell-cell or cell adhesion events apart from
regulating phagocytosis. As the role of C1qRP in these
other cell types is defined, it will be important to determine whether
this consensus motif for enhancement of phagocytosis is also
required for the functional responses of these distinct cell types.
In summary, our results demonstrate that a conserved amino acid motif
of the collagen-like domains of the defense collagens, GE(K/Q/R)GEP, is
necessary for C1qRP-induced enhancement of FcR- and
CR1-mediated phagocytosis in human monocytes. Future studies involving
both site-specific mutagenesis and the synthesis of specific peptides
that form a collagen-like triple helix would allow further resolution
of the molecular interaction mechanism, as well as the determination of
whether this peptide motif is sufficient to induce enhancement of
phagocytosis. The ability to modulate phagocytosis, a powerful
effector mechanism of the innate immune system, could be particularly
beneficial in the early stage of infection. This capacity might
limit disease from infection, while allowing the adaptive response to
be induced for future rapid and specific protective immunity.
 |
ACKNOWLEDGEMENTS |
We thank Cheryl A. Cotman and Shimul
Kumbhani for performing ELISA experiments, Dr. Kawaski for serum MBL,
Dr. G. Stahl for anti-MBL, Sajith Jayasinghe for assistance with the CD
measurements, and Dr. Thomas Poulos (University of California,
Irvine) for providing the molecular modeling expertise.
 |
FOOTNOTES |
*
These studies were supported by Grant AI41090 from National
Institutes of Health (to A. J. T.). Support for obtaining human blood
products used in this study was provided in part by Public Health
Service Research Grant M01 RR00827 from the National Center for
Research Resources.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: 3205 Biological
Sciences II, Dept. of Molecular Biology and Biochemistry, University of
California, Irvine, CA 92697. Tel.: 949-824-3268; Fax: 949-824-8551; E-mail: atenner@uci.edu.
Published, JBC Papers in Press, August 30, 2001, DOI 10.1074/jbc.M105455200
 |
ABBREVIATIONS |
The abbreviations used are:
MBL, mannan-binding
lectin;
SP-A and SP-D, surfactant proteins A and D;
hMBL, human MBL;
rMBL, recombinant MBL;
rhMBL, recombinant human MBL;
EAIgG, sheep erythrocytes opsonized with IgG anti-sheep red blood cells;
EAIgMC4b, sheep erythrocytes opsonized with IgM anti-sheep
red blood cells;
PI, phagocytic index;
SDS-PAGE, SDS-polyacrylamide gel
electrophoresis;
HSA, human serum albumin;
Del, hMBL with amino acids
69-74 deleted;
ELISA, enzyme-linked immunosorbent
assay.
 |
REFERENCES |
| 1.
|
Holmskov, U.,
Malhotra, R.,
Sim, R. B.,
and Jensenius, J. C.
(1994)
Immunol. Today
15,
67-74[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Kawasaki, N.,
Kawasaki, T.,
and Yamashina, I.
(1983)
J. Biochem.
94,
937-947[Abstract/Free Full Text]
|
| 3.
|
Drickamer, K.,
Dordal, M. S.,
and Reynolds, L.
(1986)
J. Biol. Chem.
261,
6878-6887[Abstract/Free Full Text]
|
| 4.
|
Takada, F.,
Takayama, Y.,
Hatsuse, H.,
and Kawakami, M.
(1993)
Biochem. Biophys. Res. Commun.
196,
1003-1009[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Sato, T.,
Endo, Y.,
Matsushita, M.,
and Fujita, T.
(1994)
Int. Immunol.
6,
665-669[Abstract/Free Full Text]
|
| 6.
|
Thiel, S.,
Vorup-Jensen, T.,
Stover, C. M.,
Schwaeble, W.,
Laursen, S. B.,
Poulsen, K.,
Willis, A. C.,
Eggleton, P.,
Hansen, S.,
Holmskov, U.,
Reid, K. B. M.,
and Jensenius, J. C.
(1997)
Nature
386,
506-510[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Ji, Y. H.,
Matsushita, M.,
Okada, H.,
Fujita, T.,
and Kawakami, M.
(1988)
J. Immunol.
141 (12),
4271-4275[Abstract]
|
| 8.
|
Ji, Y. H.,
Fujita, T.,
Hatsuse, H.,
Takahashi, A.,
Matsushita, M.,
and Kawakami, M.
(1993)
J. Immunol.
150,
571-578[Abstract]
|
| 9.
|
Krieger, M.,
Acton, S.,
Ashkenas, J.,
Pearson, A.,
Penman, M.,
and Resnick, D.
(1993)
J. Biol. Chem.
268,
4569-4572[Free Full Text]
|
| 10.
|
Medzhitov, R.,
and Janeway, C. A., Jr.
(1997)
Curr. Opin. Immunol.
9,
4-9[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Matsushita, M.,
Endo, Y.,
Taira, S.,
Sato, Y.,
Fujita, T.,
Ichikawa, N.,
Nakata, M.,
and Mizuochi, T.
(1996)
J. Biol. Chem.
271,
2448-2454[Abstract/Free Full Text]
|
| 12.
|
Wright, J. R.
(1997)
Physiol. Rev.
77,
931-962[Abstract/Free Full Text]
|
| 13.
|
Tenner, A. J.
(1999)
Curr. Opin. Immunol.
11,
34-42[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Kuhlman, M.,
Joiner, K.,
and Ezekowitz, R. A. B.
(1989)
J. Exp. Med.
169,
1733-1745[Abstract/Free Full Text]
|
| 15.
|
Tenner, A. J.,
Robinson, S. L.,
Borchelt, J.,
and Wright, J. R.
(1989)
J. Biol. Chem.
264,
13923-13928[Abstract/Free Full Text]
|
| 16.
|
Tenner, A. J.,
Robinson, S. L.,
and Ezekowitz, R. A. B.
(1995)
Immunity
3,
485-493[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Nepomuceno, R. R.,
Ruiz, S.,
Park, M.,
and Tenner, A. J.
(1999)
J. Immunol.
162,
3583-3589[Abstract/Free Full Text]
|
| 18.
|
Bobak, D. A.,
Gaither, T. G.,
Frank, M. M.,
and Tenner, A. J.
(1987)
J. Immunol.
138,
1150-1156[Abstract/Free Full Text]
|
| 19.
|
Tenner, A. J.,
Lesavre, P. H.,
and Cooper, N. R.
(1981)
J. Immunol.
127,
648-653[Abstract]
|
| 20.
|
Young, K. R.,
Ambrus, J. L., Jr.,
Malbran, A.,
Fauci, A. S.,
and Tenner, A. J.
(1991)
J. Immunol.
146,
3356-3364[Abstract]
|
| 21.
|
Zhao, H.,
and Stahl, G. L.
(2000)
FASEB J.
15,
A685-A685
|
| 22.
|
Guan, E.,
Robinson, S. L.,
Goodman, E. B.,
and Tenner, A. J.
(1994)
J. Immunol.
152,
4005-4016[Abstract]
|
| 23.
|
Lionetti, F. J.,
Hunt, S. M.,
and Valeri, C. R.
(1980)
in
Methods of Cell Separation
(Catsimpoolas, N., ed)
, pp. 141-156, Plenum Publishing Corp., New York
|
| 24.
|
Bobak, D. A.,
Frank, M. M.,
and Tenner, A. J.
(1986)
J. Immunol.
136,
4604-4610[Abstract]
|
| 25.
|
Ma, Y.,
Shida, H.,
and Kawasaki, T.
(1997)
J. Biochem. (Tokyo)
122,
810-818[Abstract/Free Full Text]
|
| 26.
|
Masushita, M.,
and Fujita, T.
(1992)
J. Exp. Med.
176,
1497-1502[Abstract/Free Full Text]
|
| 27.
|
Bohnsack, J. F.,
Kleinman, H. K.,
Takahashi, T.,
O'Shea, J. J.,
and Brown, E. J.
(1985)
J. Exp. Med.
161,
912-923[Abstract/Free Full Text]
|
| 28.
|
Bobak, D. A.,
Frank, M. M.,
and Tenner, A. J.
(1988)
Eur. J. Immunol.
18,
2001-2007[Medline]
[Order article via Infotrieve]
|
| 29.
|
Burdick, M. D.,
Harris, A.,
Reid, C. J.,
Iwamura, T.,
and Hollingsworth, M. A.
(1997)
J. Biol. Chem.
272,
24198-24202[Abstract/Free Full Text]
|
| 30.
|
Cooper, N. R.
(1985)
Advances in Immunology
37,
151-216[Medline]
[Order article via Infotrieve]
|
| 31.
|
Tenner, A. J.,
and Cooper, N. R.
(1980)
J. Immunol.
125,
1658-1664[Abstract]
|
| 32.
|
Bella, J.,
Eaton, M.,
Brodsky, B.,
and Berman, H. M.
(1994)
Science
266,
75-81[Abstract/Free Full Text]
|
| 33.
|
Ruiz, S.,
Henschen-Edman, A. H.,
Nagase, H.,
and Tenner, A. J.
(1999)
J. Leukocyte Biol.
66,
416-422[Abstract]
|
| 34.
|
Ruiz, S.,
Henschen-Edman, A. H.,
and Tenner, A. J.
(1995)
J. Biol. Chem.
270,
30627-30634[Abstract/Free Full Text]
|
| 35.
|
Tenner, A. J.
(1998)
Immunobiology
199,
250-264[Medline]
[Order article via Infotrieve]
|
| 36.
|
Tenner, A. J.
(1989)
Behring Inst. Mitt.
84,
220-235
|
| 37.
|
Webster, S. D.,
Park, M.,
Fonseca, M. I.,
and Tenner, A. J.
(2000)
J. Leukocyte Biol.
67,
109-116[Abstract]
|
| 38.
|
Nepomuceno, R. R.,
and Tenner, A. J.
(1998)
J. Immunol.
160,
1929-1935[Abstract/Free Full Text]
|
| 39.
| Fonseca, M. I., Carpenter, P. M., Park, M., Palmarini, G.,
Nelson, E. L., and Tenner, A. J. (2001) J. Leukocyte Biol., in press
|
| 40.
|
Dean, Y. D.,
McGreal, E. P.,
Akatsu, H.,
and Gasque, P.
(2000)
J. Biol. Chem.
275,
34382-34392[Abstract/Free Full Text]
|
| 41.
|
Petrenko, O.,
Beavis, A.,
Klaine, M.,
Kittappa, R.,
Godin, I.,
and Lemischka, I. R.
(1999)
Immunity
10,
691-700[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Lovik, G.,
Vaage, J. T.,
Dissen, E.,
Szpirer, C.,
Ryan, J. C.,
and Rolstad, B.
(2000)
Eur. J. Immunol.
30,
3355-3362[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. P. Lillis, M. C. Greenlee, I. Mikhailenko, S. V. Pizzo, A. J. Tenner, D. K. Strickland, and S. S. Bohlson
Murine Low-Density Lipoprotein Receptor-Related Protein 1 (LRP) Is Required for Phagocytosis of Targets Bearing LRP Ligands but Is Not Required for C1q-Triggered Enhancement of Phagocytosis
J. Immunol.,
July 1, 2008;
181(1):
364 - 373.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Fraser, S. S. Bohlson, N. Jasinskiene, N. Rawal, G. Palmarini, S. Ruiz, R. Rochford, and A. J. Tenner
C1q and MBL, components of the innate immune system, influence monocyte cytokine expression
J. Leukoc. Biol.,
July 1, 2006;
80(1):
107 - 116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Cimerman, G. Arnaud, and X. Foissac
Stolbur phytoplasma genome survey achieved using a suppression subtractive hybridization approach with high specificity.
Appl. Envir. Microbiol.,
May 1, 2006;
72(5):
3274 - 3283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Hart, K. A. Ceonzo, L. A. Shaffer, K. Takahashi, R. P. Rother, W. R. Reenstra, J. A. Buras, and G. L. Stahl
Gastrointestinal Ischemia-Reperfusion Injury Is Lectin Complement Pathway Dependent without Involving C1q
J. Immunol.,
May 15, 2005;
174(10):
6373 - 6380.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. S. Butler, D. Sim, E. Tam, D. Devine, and C. M. Overall
Mannose-binding Lectin (MBL) Mutants Are Susceptible to Matrix Metalloproteinase Proteolysis. POTENTIAL ROLE IN HUMAN MBL DEFICIENCY
J. Biol. Chem.,
May 10, 2002;
277(20):
17511 - 17519.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|